Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Jorge Labrador; Elisa Luno; Edo Vellenga; Salut Brunet; Jose Gonzalez-Campose; Maria C. Chillon; Aleksandra Holowiecka; Jordi Esteve; Juan Bergua; Jose D. Gonzalez-Sanmiguel; Cristina Gil; M. Tormo; Olga Salamero; Felix Manso; Isolda Fernandez; Javier de laSerna; Maria-Jose Moreno; M. Perez-Encinas; Isabel Krsnik; Josep-Maria Ribera; Jose Cervera; Maria J. Calasanz; Blanca Boluda; Marta Sobas; Bob Lowenberg; Miguel A. Sanz; Pau Montesinos; L. Palmer; null Fernandez; S. Ciarlo; F. Bezares; F. Rojas; H. Longoni; M. Gelemur; P. Fazio; C. Canepa; S. Saba; G. Balladares; P. Negri; M. Giunta; J. Milone; M. Prates; D. Lafalse; C. Sossa; F. Jaramillo; J. Mayer; F. Ramos; J. Martinez; M. R. de Groot; H. C. Schouten; Programa Español de Tratamientos en Hematología (PETHEMA) group; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Polish Adult Leukemia Group, PALG; Grupo Argentino de Tratamiento de la Leucemia Aguda, GATLA

doi:10.1080/10428194.2018.1522438

Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Jorge Labrador, Elisa Luno, Edo Vellenga, Salut Brunet, Jose Gonzalez-Campose, Maria C. Chillon, Aleksandra Holowiecka, Jordi Esteve, Juan Bergua, Jose D. Gonzalez-Sanmiguel, Cristina Gil, M. Tormo, Olga Salamero, Felix Manso, Isolda Fernandez, Javier de laSerna, Maria-Jose Moreno, M. Perez-Encinas, Isabel Krsnik, Josep-Maria RiberaJose Cervera, Maria J. Calasanz, Blanca Boluda, Marta Sobas, Bob Lowenberg, Miguel A. Sanz, Pau Montesinos^*, L. Palmer, Fernandez, S. Ciarlo, F. Bezares, F. Rojas, H. Longoni, M. Gelemur, P. Fazio, C. Canepa, S. Saba, G. Balladares, P. Negri, M. Giunta, J. Milone, M. Prates, D. Lafalse, C. Sossa, F. Jaramillo, J. Mayer, F. Ramos, J. Martinez, M. R. de Groot, H. C. Schouten, Programa Español de Tratamientos en Hematología (PETHEMA) group, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Polish Adult Leukemia Group, PALG, Grupo Argentino de Tratamiento de la Leucemia Aguda, GATLA

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Web of Science)

Abstract

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of >= 2 ACA, and a very CK (CK+) as >= 3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with

Original language	English
Pages (from-to)	1146-1155
Number of pages	10
Journal	Leukemia & Lymphoma
Volume	60
Issue number	5
DOIs	https://doi.org/10.1080/10428194.2018.1522438
Publication status	Published - 16 Apr 2019

Keywords

Acute promyelocytic leukemia
complex karyotype
ATRA
chemotherapy
prognostic
relapse
TRANS-RETINOIC ACID
ADDITIONAL CHROMOSOME-ABNORMALITIES
RISK-ADAPTED TREATMENT
ARSENIC TRIOXIDE
ANTHRACYCLINE MONOCHEMOTHERAPY
PROGNOSTIC-SIGNIFICANCE
CONSOLIDATION THERAPY
CYTOGENETIC CHANGES
FLT3 MUTATIONS
PETHEMA

Access to Document

10.1080/10428194.2018.1522438

Cite this

Labrador, J., Luno, E., Vellenga, E., Brunet, S., Gonzalez-Campose, J., Chillon, M. C., Holowiecka, A., Esteve, J., Bergua, J., Gonzalez-Sanmiguel, J. D., Gil, C., Tormo, M., Salamero, O., Manso, F., Fernandez, I., de laSerna, J., Moreno, M-J., Perez-Encinas, M., Krsnik, I., ... Grupo Argentino de Tratamiento de la Leucemia Aguda, GATLA (2019). Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia & Lymphoma, 60(5), 1146-1155. https://doi.org/10.1080/10428194.2018.1522438

@article{d44f681eb4e94ee9836b86089a19546f,

title = "Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy",

abstract = "Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of >= 2 ACA, and a very CK (CK+) as >= 3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with",

keywords = "Acute promyelocytic leukemia, complex karyotype, ATRA, chemotherapy, prognostic, relapse, TRANS-RETINOIC ACID, ADDITIONAL CHROMOSOME-ABNORMALITIES, RISK-ADAPTED TREATMENT, ARSENIC TRIOXIDE, ANTHRACYCLINE MONOCHEMOTHERAPY, PROGNOSTIC-SIGNIFICANCE, CONSOLIDATION THERAPY, CYTOGENETIC CHANGES, FLT3 MUTATIONS, PETHEMA",

author = "Jorge Labrador and Elisa Luno and Edo Vellenga and Salut Brunet and Jose Gonzalez-Campose and Chillon, {Maria C.} and Aleksandra Holowiecka and Jordi Esteve and Juan Bergua and Gonzalez-Sanmiguel, {Jose D.} and Cristina Gil and M. Tormo and Olga Salamero and Felix Manso and Isolda Fernandez and {de laSerna}, Javier and Maria-Jose Moreno and M. Perez-Encinas and Isabel Krsnik and Josep-Maria Ribera and Jose Cervera and Calasanz, {Maria J.} and Blanca Boluda and Marta Sobas and Bob Lowenberg and Sanz, {Miguel A.} and Pau Montesinos and L. Palmer and Fernandez and S. Ciarlo and F. Bezares and F. Rojas and H. Longoni and M. Gelemur and P. Fazio and C. Canepa and S. Saba and G. Balladares and P. Negri and M. Giunta and J. Milone and M. Prates and D. Lafalse and C. Sossa and F. Jaramillo and J. Mayer and F. Ramos and J. Martinez and {de Groot}, {M. R.} and Schouten, {H. C.} and {Programa Espa{\~n}ol de Tratamientos en Hematolog{\'i}a (PETHEMA) group} and {Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)} and {Polish Adult Leukemia Group, PALG} and {Grupo Argentino de Tratamiento de la Leucemia Aguda, GATLA}",

note = "Funding Information: This work was partially financed with FEDER funds [CIBERONC (CB16/12/00284)]. We thank the patients who volunteered to participate in this trial, their families, and clinicians responsible for the patients. The authors also thank all responsible for the local cytogenetic laboratories. The authors thank Carlos Pastorini, Mar{\'i}a D. Garc{\'i}a and Mar Benlloch for data collection and management. Publisher Copyright: {\textcopyright} 2018, {\textcopyright} 2018 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = apr,

day = "16",

doi = "10.1080/10428194.2018.1522438",

language = "English",

volume = "60",

pages = "1146--1155",

journal = "Leukemia & Lymphoma",

issn = "1042-8194",

publisher = "Routledge/Taylor & Francis Group",

number = "5",

}

Labrador, J, Luno, E, Vellenga, E, Brunet, S, Gonzalez-Campose, J, Chillon, MC, Holowiecka, A, Esteve, J, Bergua, J, Gonzalez-Sanmiguel, JD, Gil, C, Tormo, M, Salamero, O, Manso, F, Fernandez, I, de laSerna, J, Moreno, M-J, Perez-Encinas, M, Krsnik, I, Ribera, J-M, Cervera, J, Calasanz, MJ, Boluda, B, Sobas, M, Lowenberg, B, Sanz, MA, Montesinos, P, Palmer, L, Fernandez, Ciarlo, S, Bezares, F, Rojas, F, Longoni, H, Gelemur, M, Fazio, P, Canepa, C, Saba, S, Balladares, G, Negri, P, Giunta, M, Milone, J, Prates, M, Lafalse, D, Sossa, C, Jaramillo, F, Mayer, J, Ramos, F, Martinez, J, de Groot, MR, Schouten, HC, Programa Español de Tratamientos en Hematología (PETHEMA) group, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Polish Adult Leukemia Group, PALG & Grupo Argentino de Tratamiento de la Leucemia Aguda, GATLA 2019, 'Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy', Leukemia & Lymphoma, vol. 60, no. 5, pp. 1146-1155. https://doi.org/10.1080/10428194.2018.1522438

TY - JOUR

T1 - Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

AU - Labrador, Jorge

AU - Luno, Elisa

AU - Vellenga, Edo

AU - Brunet, Salut

AU - Gonzalez-Campose, Jose

AU - Chillon, Maria C.

AU - Holowiecka, Aleksandra

AU - Esteve, Jordi

AU - Bergua, Juan

AU - Gonzalez-Sanmiguel, Jose D.

AU - Gil, Cristina

AU - Tormo, M.

AU - Salamero, Olga

AU - Manso, Felix

AU - Fernandez, Isolda

AU - de laSerna, Javier

AU - Moreno, Maria-Jose

AU - Perez-Encinas, M.

AU - Krsnik, Isabel

AU - Ribera, Josep-Maria

AU - Cervera, Jose

AU - Calasanz, Maria J.

AU - Boluda, Blanca

AU - Sobas, Marta

AU - Lowenberg, Bob

AU - Sanz, Miguel A.

AU - Montesinos, Pau

AU - Palmer, L.

AU - Fernandez, null

AU - Ciarlo, S.

AU - Bezares, F.

AU - Rojas, F.

AU - Longoni, H.

AU - Gelemur, M.

AU - Fazio, P.

AU - Canepa, C.

AU - Saba, S.

AU - Balladares, G.

AU - Negri, P.

AU - Giunta, M.

AU - Milone, J.

AU - Prates, M.

AU - Lafalse, D.

AU - Sossa, C.

AU - Jaramillo, F.

AU - Mayer, J.

AU - Ramos, F.

AU - Martinez, J.

AU - de Groot, M. R.

AU - Schouten, H. C.

AU - Programa Español de Tratamientos en Hematología (PETHEMA) group

AU - Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

AU - Polish Adult Leukemia Group, PALG

AU - Grupo Argentino de Tratamiento de la Leucemia Aguda, GATLA

N1 - Funding Information: This work was partially financed with FEDER funds [CIBERONC (CB16/12/00284)]. We thank the patients who volunteered to participate in this trial, their families, and clinicians responsible for the patients. The authors also thank all responsible for the local cytogenetic laboratories. The authors thank Carlos Pastorini, María D. García and Mar Benlloch for data collection and management. Publisher Copyright: © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of >= 2 ACA, and a very CK (CK+) as >= 3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with

AB - Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of >= 2 ACA, and a very CK (CK+) as >= 3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with

KW - Acute promyelocytic leukemia

KW - complex karyotype

KW - ATRA

KW - chemotherapy

KW - prognostic

KW - relapse

KW - TRANS-RETINOIC ACID

KW - ADDITIONAL CHROMOSOME-ABNORMALITIES

KW - RISK-ADAPTED TREATMENT

KW - ARSENIC TRIOXIDE

KW - ANTHRACYCLINE MONOCHEMOTHERAPY

KW - PROGNOSTIC-SIGNIFICANCE

KW - CONSOLIDATION THERAPY

KW - CYTOGENETIC CHANGES

KW - FLT3 MUTATIONS

KW - PETHEMA

U2 - 10.1080/10428194.2018.1522438

DO - 10.1080/10428194.2018.1522438

M3 - Article

C2 - 30526152

SN - 1042-8194

VL - 60

SP - 1146

EP - 1155

JO - Leukemia & Lymphoma

JF - Leukemia & Lymphoma

IS - 5

ER -